A federal consultative group voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-mandatory. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of public hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could redefine how the agency handles a part of the wellness market that is surging ahead. Patient groups are waiting to see if the regulator moves in step. A spokesperson offered no set date for a follow-up. Critics argue the change would open up access to products users find useful. Opponents warn that looser rules could leave gaps in oversight across a fast-scaling market. The vote only lays the groundwork for change, and the final call rests with the federal regulator.